In this detailed medical educational webinar hosted on Rheuma TV, experts examine the clinical positioning, efficacy, and safety profile of Iguratimod when utilized as a combination Disease-Modifying Antirheumatic Drug (DMARD) for treating active Rheumatoid Arthritis (RA).
The session covers essential clinical insights for managing complex RA presentations, including:
Mechanism of Action & Pharmacokinetics: Understanding how Iguratimod inhibits inflammatory cytokine production (including IL-1, IL-6, and TNF-alpha) and suppresses nuclear factor-kappa B (NF-κB) activation.
Clinical Rationale for Combination Therapy: Evaluating therapeutic outcomes when combining Iguratimod with conventional synthetic DMARDs (csDMARDs) such as Methotrexate (MTX) versus monotherapy.
Patient Selection & Dosing Strategies: Guidelines for identifying appropriate candidates with inadequate responses to standard therapies, recommended dosage escalation schedules, and clinical monitoring.
Safety & Tolerability Profile: Managing potential adverse events, liver enzyme monitoring, and long-term safety considerations in clinical practice.
Ask your Questions to our Experts
Disclaimer:
The information in this educational activity is provided for general medical education purposes meant for registered medical practitioners only. The activity is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by Rheumatv.com or the Sponsor. In no event will Rheumatv, the Sponsor or, the authors/faculty be liable for any decision made or action taken in reliance upon the information provided through this CME activity. All CMEs are recorded to be used for research and information purposes only. Rheumatv at the request of Sponsor, may share your details such as name, location, and session feedback for research and information purposes only.